Hansa Biopharma submits responses to outstanding questions from EMA on May 26. Review is on track; an opinion from CHMP is expected by end of June.
(WorldNews Sweden)

05/25/2020 Lund May 25, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the ongoing EMA review of imlifidase for a potential marketing authorization in Europe is on track. A CHMP opinion is...